Becton, Dickinson and Company (BDXA)

Becton Dickinson and Co (NYSE:BDX) reported fourth-quarter adjusted earnings of $3.96, beating the consensus of $3.92.

For my followup on medtech stock Becton, Dickinson and Company, I'm reaffirming my prior buy rating, agreeing with the Wall St consensus today. Becton, Dickinson's growing and globally diverse portfolio should continue to address the macro clinical demand in several areas. Despite unsteady cashflow growth trends, BDX continued to grow dividends steadily while also making major capital investments.

Becton Dickinson said on Wednesday that its Chief Financial Officer Chris DelOrefice will depart the company, effective December 5, to pursue a new professional opportunity.

BDX is now attractively valued with a forward PE of 13.7, well below its historical average, making it a compelling value stock. Strong growth in Pharmaceutical Systems and Interventional segments, margin expansion, and a robust innovation pipeline drive business momentum. The upcoming Waters Corp. spin-out will focus BDX on high-growth, recurring revenue segments, enhancing long-term earnings potential.

As the healthcare industry continues to rebound from global disruptions, companies like Becton, Dickinson, and Company BDX are reporting robust financial performances that highlight their resilience and strategic adaptability. The company's stock is trading higher on Thursday on better-than-expected third-quarter 2025 earnings.

Becton Dickinson raised its forecast for annual profit on Thursday, after beating Wall Street estimates for third-quarter profit and sales on strong demand for its drug-delivery devices.

Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 billion of the proceeds to buy back stock.

Shares of Becton Dickinson and Company BDX are currently in its 17th phase of the 18-phase Adhishthana Cycle, and signs point toward continued underperformance and consolidation, likely lasting until early June 2027. Here's a breakdown of why the stock's structure looks weak under the lens of the Adhishthana Principles, our proprietary cyclical framework combining behavioral archetypes, timing structures, and quantitative signals.

Becton, Dickinson is significantly undervalued, trading at 12.3x earnings with a 2.5% dividend yield, the highest in a decade. The company boasts a 53-year streak of dividend growth, excellent dividend safety, and a conservative payout ratio, making it a reliable Dividend King. Despite tariff headwinds, competition, and restructuring risks, BDX's innovation, acquisitions, and organic growth support long-term revenue and EPS expansion.

Becton Dickinson, and Company BDX lowered its fiscal year 2025 guidance and provided an estimated tariff impact on Thursday.

Becton Dickinson & Co.'s stock fell more than 15% on Thursday toward its worst one-day loss in 26 years after the medical-products maker said global cuts in research funding are impacting its research instrument sales.

CNBC's Jim Cramer explains why he is keeping an eye on shares of Becton Dickinson.

Medical device maker Becton Dickinson lowered its annual profit forecast on Thursday, in anticipation of a potential hit from U.S. President Donald Trump's tariffs, sending its shares down 5% in premarket trading.

Becton, Dickinson and Company is a leading medical device firm specializing in medical supplies, devices, laboratory equipment, and diagnostic products. BDX operates in three segments: BD Medical, BD Life Sciences, and BD Interventional, with plans to spin off its Biosciences and Diagnostic Solutions business in 2026. BDX has struggled over the past decade, with a 10-year CAGR of only 5.1%.

Medical device maker Becton Dickinson has begun discussions to sell its life sciences division, valued at $21 billion, and is in talks with competitors such as Thermo Fisher Scientific and Danaher , the Financial Times reported on Tuesday.

Becton Dickinson gets rating buy in my first coverage of this stock. Macro demand for medtech and surgical supplies could favor this globally diversified firm with an active portfolio and growth pipeline. The firm is a proven dividend grower and cashflow generator with low debt/equity and investment-grade credit ratings.